MX365192B - Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. - Google Patents

Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.

Info

Publication number
MX365192B
MX365192B MX2014014895A MX2014014895A MX365192B MX 365192 B MX365192 B MX 365192B MX 2014014895 A MX2014014895 A MX 2014014895A MX 2014014895 A MX2014014895 A MX 2014014895A MX 365192 B MX365192 B MX 365192B
Authority
MX
Mexico
Prior art keywords
cancer therapy
related compounds
medical use
bendamustine
bendamustine derivatives
Prior art date
Application number
MX2014014895A
Other languages
English (en)
Other versions
MX2014014895A (es
Inventor
Schickaneder Helmut
Schickaneder Christian
Buschauer Armin
Huber Stefan
Limmert Michael
Bernhardt Günther
Lubbe Mathias
Hofmeier Harald
Original Assignee
Synbias Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synbias Pharma Ag filed Critical Synbias Pharma Ag
Publication of MX2014014895A publication Critical patent/MX2014014895A/es
Publication of MX365192B publication Critical patent/MX365192B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de bendamustina y compuestos relacionados de las fórmulas (VII) (VIII) y (IX), y los usos médicos de los mismos en particular en terapia contra el cáncer.
MX2014014895A 2012-06-19 2013-06-14 Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. MX365192B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661374P 2012-06-19 2012-06-19
US201261670158P 2012-07-11 2012-07-11
PCT/EP2013/062347 WO2013189847A1 (en) 2012-06-19 2013-06-14 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy

Publications (2)

Publication Number Publication Date
MX2014014895A MX2014014895A (es) 2015-06-17
MX365192B true MX365192B (es) 2019-05-23

Family

ID=48628661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014895A MX365192B (es) 2012-06-19 2013-06-14 Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.

Country Status (12)

Country Link
US (2) US10526290B2 (es)
EP (1) EP2861564B1 (es)
JP (1) JP6153606B2 (es)
KR (1) KR101955065B1 (es)
CN (1) CN104395296A (es)
BR (1) BR112014031556B1 (es)
CA (1) CA2875455C (es)
ES (1) ES2694757T3 (es)
MX (1) MX365192B (es)
RU (1) RU2695383C2 (es)
UA (1) UA117809C2 (es)
WO (1) WO2013189847A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029706B1 (ru) 2012-11-12 2018-05-31 Игнайта, Инк. Сложные алкиловые эфиры бендамустина и способы их применения
EP2886536A1 (en) * 2013-12-19 2015-06-24 Helmut Schickaneder Bendamustine derivatives as anti-proliferative agents
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
MX2020004901A (es) 2017-11-13 2020-09-09 Ecolab Usa Inc Un proceso novedoso homogeneo en un solo paso para la preparacion a gran escala de bencimidazoles sustituidos en la posicion 2.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD34727A1 (de) * 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
JPH08510469A (ja) * 1993-05-25 1996-11-05 オークランド ユニサービシーズ リミテッド ニトロベンジルマスタード四級塩およびその低酸素選択性細胞毒剤としての利用
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US20090264426A1 (en) * 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
CA2737495A1 (en) 2008-10-08 2010-04-15 Cephalon, Inc. Processes for the preparation of bendamustine
US20130217888A1 (en) * 2010-11-01 2013-08-22 Shailpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
DK2656843T3 (en) * 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof

Also Published As

Publication number Publication date
US10294208B2 (en) 2019-05-21
HK1209725A1 (en) 2016-04-08
JP2015520200A (ja) 2015-07-16
CA2875455A1 (en) 2013-12-27
ES2694757T3 (es) 2018-12-27
CA2875455C (en) 2020-03-10
UA117809C2 (uk) 2018-10-10
EP2861564A1 (en) 2015-04-22
WO2013189847A1 (en) 2013-12-27
JP6153606B2 (ja) 2017-06-28
US20150152066A1 (en) 2015-06-04
BR112014031556B1 (pt) 2019-10-29
EP2861564B1 (en) 2018-08-08
RU2014146896A (ru) 2016-08-10
BR112014031556A2 (pt) 2015-12-22
KR101955065B1 (ko) 2019-03-06
RU2695383C2 (ru) 2019-07-23
US10526290B2 (en) 2020-01-07
MX2014014895A (es) 2015-06-17
KR20150020581A (ko) 2015-02-26
US20170313663A1 (en) 2017-11-02
CN104395296A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
IN2015DN01156A (es)
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12017502141A1 (en) Compounds and their methods of use
PH12013501600A1 (en) Novel heterocyclic derivatives
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
NZ749217A (en) Androgen receptor modulator and uses thereof
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX364486B (es) Derivados de piridazinona-amidas.
EA201400178A1 (ru) Лечение рака молочной железы
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
IN2014DN06104A (es)
PH12015501088A1 (en) Dimeric compounds
GB201209587D0 (en) Therapeutic compounds
PH12015501038A1 (en) Inhibitors of iap
PH12015500399A1 (en) Azaindolines
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
IN2014KN01772A (es)
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
TN2013000327A1 (en) Novel heterocyclic derivatives

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SYNBIAS PHARMA AG

FG Grant or registration